MTBVAC PRIME_ Tuberculosis vaccine for newborns
MTBVAC BOOSTER_ Tuberculosis vaccine for adolescents and adults
Tuberculosis remains one of the most lethal communicable diseases in the world, with 10 million new cases and 1.5 million deaths per year. The figures in the WHO report for 2016 place this disease for the first time with the highest mortality rate worldwide, surpassing AIDS.
For almost 100 years, BCG (Bacillus Calmette-Guerin) has been the only vaccine against tuberculosis that protects children against the most serious forms of this disease. However, it has been shown that BCG is no longer effective against the most contagious and widespread disease, the pulmonary tuberculosis.
Within the current portfolio of vaccines under development worldwide against tuberculosis, our MTBVAC vaccine is one of the strongest candidates and most promising in the opinion of experts worldwide.
MTBVAC, is a live attenuated vaccine of M. tuberculosis (Mycobacterium tuberculosis) designed by the genetic research group of Dr. Carlos Martin Montañés of the Department of Microbiology at the University of Zaragoza and Brigitte Gicquel at the Institut Pasteur of Paris.
MTBVAC is currently in Phase 2 of clinical trials in both newborns and adults.
Biofabri is responsible for the manufacture of MTBVAC as a live attenuated lyophilized vaccine and aims to license MTBVAC against tuberculosis in both, adults and newborns.
The MTBVAC vaccine is currently in Phase 2 clinical trials with both newborns and adults in South Africa, one of the largest endemic countrie.
Biofabri is also working on the development of other new and innovative biologicals.